A Clinical Brexanolone Treatment Program at an Academic Medical Center- challenges and lessons learned with patient selection and post 30 day outcomes
September 13, 2021
Brexanolone (Zulresso) is the first Federal Drug Administration (FDA) approved drug for the treatment of postpartum depression (PPD). Brexanolone is a positive allosteric modulator of the GABAA receptor, and is given over 60 hours by infusion in a medical setting. This drug has been shown to be effective at significantly reducing...